TESARO Inc (NASDAQ:TSRO) reported earnings of ($3.04) per share missing Walls Streets expectations.

ME Staff
-
0

TESARO Inc (NASDAQ:TSRO) reported Q2 2018 earnings this Afternoon, coming in at ($3.04) per share, missing Wall Street’s estimates of ($2.64) per Share. Revenue for the quarter came in at $57.21 million missing the streets estimates of $65.50 million

Recent Insider Trading for TESARO Inc (NASDAQ:TSRO)

  • On 6/12/2018 Lawrence M Alleva, Director, sold 7,142 with an average share price of $43.11 per share and the total transaction amounting to $307,891.62.
  • On 3/8/2018 Orlando Oliveira, SVP, sold 3,000 with an average share price of $69.88 per share and the total transaction amounting to $209,640.00.
  • On 3/6/2018 Peter J Barris, Major Shareholder, bought 145,532 with an average share price of $57.40 per share and the total transaction amounting to $8,353,536.80.
  • On 3/5/2018 David M Mott, Director, bought 61,437 with an average share price of $58.83 per share and the total transaction amounting to $3,614,338.71.
  • On 3/2/2018 David M Mott, Director, bought 68,302 with an average share price of $55.56 per share and the total transaction amounting to $3,794,859.12.
  • On 3/2/2018 Enterprise Associates 13 L New, Major Shareholder, bought 54,642 with an average share price of $55.56 per share and the total transaction amounting to $3,035,909.52.



    About Company
    Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

    Recent Analyst Rating for TESARO Inc (NASDAQ:TSRO)



      Recent Trading for TESARO Inc (NASDAQ:TSRO)
      Shares of TESARO Inc closed the previous trading session at 35.28 up +0.55 1.58% with 34.37 shares trading hands.